Released Nov 3, 2026, after the close
10-Q filed Nov 3, 2026, 34 days after period end · 0001714899-26-000109
Net product revenue was $17.8 million for the quarter ended September 30, 2026, reflecting AVLAYAH’s second full quarter of commercial availability in the United States following FDA approval in March 2026.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $17.78M | $0.00 | $0.00 | $1.27M |
| Net Income | $70.13M | -$126.90M | -$107.19M |
Denali Therapeutics Inc. · CIK 1714899 · Engraved from SEC EDGAR
| -$99.35M |
| EPS Diluted | $0.37 | -$0.74 | -$0.63 | -$0.72 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Denali Therapeutics reported net product revenue of $17.8 million for the quarter ended September 30, 2026, and expects fourth-quarter 2026 net product revenue of $30.0 million to $32.0 million.¶1¶2
Net income was $70.1 million for the quarter ended September 30, 2026, including a one-time $194.0 million net gain on the sale of a Priority Review Voucher.¶3¶4
Cash, cash equivalents and marketable securities were approximately $1.0 billion as of September 30, 2026.¶5
Research and development expenses were $106.1 million, compared to $102.0 million a year earlier, and selling, general and administrative expenses were $37.5 million, compared to $35.5 million.¶6¶7